ANGOANGIODYNAMICS INC
- BusinessWire
AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer
Policy Applies Medical Necessity Criteria Across Medicare Administrative Contractor (MAC) Jurisdictions for Eligible Prostate and Liver Cancer Patients AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative ...
- Analyst Upgrades
HC Wainwright & Co. Maintains Buy on AngioDynamics, Lowers Price Target to $18
HC Wainwright & Co. analyst Yi Chen maintains AngioDynamics with a Buy and lowers the price target from $19 to $18. ...
- Earnings Call Transcripts
AngioDynamics, Inc. First Quarter of Fiscal 2027 Earnings Conference Call - ANGIODYNAMICS INC
Good morning, and welcome to the AngioDynamics Fiscal Year 2027 First Quarter Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As ...
- BusinessWire
AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability
Delivered its eighth consecutive quarter of double-digit Med Tech segment growth and positive adjusted EBITDA AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on ...
- BusinessWire
AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer
Medical Technology Executive Brings More than 20 years of Leadership Experience, Including Cardiovascular, Endovascular and Oncology Markets, with a Track Record of Accelerating Growth and Improving Profitability Jim ...
- BusinessWire
AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence
Investigator-Led Study Will Evaluate Imaging Biomarkers That May Help Predict Thrombectomy Success and Inform Long-Term PE Care AngioDynamics, Inc. (NASDAQ:ANGO), a medical technology company focused on restoring ...
- BusinessWire
AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026
AngioDynamics, Inc. (NASDAQ:ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today ...
- Earnings Call Transcripts
CG 46TH ANNUAL GROWTH CONFERENCE - ANGIODYNAMICS INC
Thanks, everyone, for joining. My name is John Young. I'm one of Canaccord's senior medtech analysts, and we're thrilled to host Angio Dynamics. With us today is CEO Jim Clemmer and CFO Steve Trowbridge. We saw a very st ...
- Earnings Call Transcripts
CG 46TH ANNUAL GROWTH CONFERENCE - ANGIODYNAMICS INC
Thanks, everyone, for joining. My name is John Young. I'm one of Canaccord's senior medtech analysts, and we're thrilled to host Angio Dynamics. With us today is CEO Jim Clemmer and CFO Steve Trowbridge. We saw a very st ...
- BusinessWire
AngioDynamics to Participate in Upcoming Investor Conferences
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient ...
- Analyst Upgrades
HC Wainwright & Co. Maintains Buy on AngioDynamics, Raises Price Target to $19
HC Wainwright & Co. analyst Yi Chen maintains AngioDynamics with a Buy and raises the price target from $16 to $19. ...
- Analyst Upgrades
Canaccord Genuity Maintains Buy on AngioDynamics, Raises Price Target to $20
Canaccord Genuity analyst John Young maintains AngioDynamics with a Buy and raises the price target from $16 to $20. ...
- BusinessWire
AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability
Delivered its seventh consecutive quarter of double-digit Med Tech segment growth and positive adjusted EBITDA AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on ...
- BusinessWire
AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026
AngioDynamics, Inc. (NASDAQ:ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today ...
- BusinessWire
AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)
Prospective Feasibility Study to Examine IRE as a Tissue-Sparing, Minimally Invasive Option for Men with BPH-Related Lower Urinary Tract Symptoms AngioDynamics, Inc. (NASDAQ:ANGO), a medical technology company focused ...
- BusinessWire
AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect
Palmetto GBA Medicare Coverage Effective July 5, 2026 Advances NanoKnife IRE Reimbursement Access in Prostate and Liver Cancer, Building on Category I CPT Codes Toward Broader National Payer Coverage AngioDynamics, ...
- BusinessWire
AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient ...
- BusinessWire
AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer
Pivotal U.S. Data Show Sustained Oncologic Control and Safety Profile at 24 months Results Presented at AUA 2026 AngioDynamics, Inc. (NASDAQ:ANGO), a medical technology company focused on restoring healthy blood ...
- Analyst Upgrades
Canaccord Genuity Maintains Buy on AngioDynamics, Lowers Price Target to $16
Canaccord Genuity analyst John Young maintains AngioDynamics with a Buy and lowers the price target from $18 to $16. ...
- BusinessWire
AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability
Med Tech segment delivered its sixth consecutive quarter of double-digit growth Strong adjusted EBITDA Third consecutive quarter the Company raised full year FY 2026 guidance for net sales and Adjusted ...
- BusinessWire
AngioDynamics to Present at the 25th Annual Needham Virtual Healthcare Conference
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient ...
- BusinessWire
AngioDynamics to Report Fiscal 2026 Third Quarter Results on April 2, 2026
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient ...
- BusinessWire
AngioDynamics to Present at the Leerink Partners Global Healthcare Conference
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient ...
- BusinessWire
AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation Platform
Growing Clinical Evidence and Physician Adoption Broaden NanoKnife IRE Technology as Treatment Option for Major Solid Tumor Types AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology ...
- BusinessWire
AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care
The ALPHA-PE Research Fund Supports Independent, Physician-Led Studies to Advance Real-World PE Evidence AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring ...